SC-236
| SC-236 | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
SC-236 is a selective cyclooxygenase-2 (COX-2) inhibitor that has been studied for its potential use in treating inflammation and pain. COX-2 inhibitors are a class of drugs that specifically target the COX-2 enzyme, which is responsible for the synthesis of pro-inflammatory prostaglandins.
Mechanism of Action[edit]
SC-236 works by selectively inhibiting the COX-2 enzyme, thereby reducing the production of pro-inflammatory prostaglandins. This action helps to alleviate inflammation and pain without affecting the COX-1 enzyme, which is important for maintaining the protective lining of the stomach and regulating blood platelets.
Pharmacokinetics[edit]
The pharmacokinetics of SC-236 involve its absorption, distribution, metabolism, and excretion. SC-236 is absorbed into the bloodstream after oral administration and is distributed throughout the body. It is metabolized primarily in the liver and excreted through the kidneys.
Clinical Applications[edit]
SC-236 has been investigated for its potential use in treating conditions such as arthritis, cancer, and other inflammatory diseases. Its selective inhibition of COX-2 makes it a promising candidate for reducing inflammation with fewer gastrointestinal side effects compared to non-selective NSAIDs.
Research and Development[edit]
Research on SC-236 has focused on its efficacy and safety profile. Studies have shown that SC-236 can effectively reduce inflammation and pain in animal models. However, further clinical trials are necessary to fully understand its potential benefits and risks in humans.
Side Effects[edit]
As with other COX-2 inhibitors, potential side effects of SC-236 may include cardiovascular risks, such as an increased risk of heart attack or stroke. Gastrointestinal side effects are generally less common compared to non-selective NSAIDs.
Regulatory Status[edit]
As of the latest updates, SC-236 is still under investigation and has not been approved for clinical use by major regulatory agencies such as the FDA or EMA.
